235 related articles for article (PubMed ID: 18615840)
1. The absorption, distribution, metabolism and elimination of bevirimat in rats.
Bullock P; Larsen D; Press R; Wehrman T; Martin DE
Biopharm Drug Dispos; 2008 Oct; 29(7):396-405. PubMed ID: 18615840
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic properties and tolerability of bevirimat and atazanavir in healthy volunteers: an open-label, parallel-group study.
Martin DE; Galbraith H; Schettler J; Ellis C; Doto J
Clin Ther; 2008 Oct; 30(10):1794-805. PubMed ID: 19014835
[TBL] [Abstract][Full Text] [Related]
3. Disposition and metabolism of the new hypocholesterolemic compound S-8921 in rats and dogs.
Yamaguchi T; Nakajima Y; Mizobuchi M; Inazawa K; Kanazu T; Kadono K; Ohkawa T; Iwatani K
Arzneimittelforschung; 1998 Oct; 48(10):995-1006. PubMed ID: 9825117
[TBL] [Abstract][Full Text] [Related]
4. An oral human drug absorption study to assess the impact of site of delivery on the bioavailability of bevirimat.
Connor A; Evans P; Doto J; Ellis C; Martin DE
J Clin Pharmacol; 2009 May; 49(5):606-12. PubMed ID: 19304891
[TBL] [Abstract][Full Text] [Related]
5. Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3',3'-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection.
Smith PF; Ogundele A; Forrest A; Wilton J; Salzwedel K; Doto J; Allaway GP; Martin DE
Antimicrob Agents Chemother; 2007 Oct; 51(10):3574-81. PubMed ID: 17638699
[TBL] [Abstract][Full Text] [Related]
6. Absorption, distribution, metabolism and excretion of telmesteine, a mucolitic agent, in rat.
Lee J; Son J; Rhee SW; Kim DH
Xenobiotica; 2003 Jul; 33(7):755-65. PubMed ID: 12893524
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics, protein binding and metabolic profile of 3H-icometasone enbutate following intravenous, oral and intratracheal administrations to Sprague-Dawley rats.
Duchêne P; Giudicelli MD; Neau B; Gronfier A; Firmin Y; Villax P; Saivin S; Houin G
Arzneimittelforschung; 1998 Apr; 48(4):371-8. PubMed ID: 9608879
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics, biliary excretion, and tissue distribution of novel anti-HIV agents, cosalane and dihydrocosalane, in Sprague-Dawley rats.
Kuchimanchi KR; Udata C; Johnston TP; Mitra AK
Drug Metab Dispos; 2000 Apr; 28(4):403-8. PubMed ID: 10725308
[TBL] [Abstract][Full Text] [Related]
9. Pre-clinical pharmacokinetics of the cyclooxygenase-inhibiting nitric oxide donor (CINOD) AZD3582.
Fagerholm U; Breuer O; Swedmark S; Hoogstraate J
J Pharm Pharmacol; 2005 May; 57(5):587-97. PubMed ID: 15901348
[TBL] [Abstract][Full Text] [Related]
10. Studies on the metabolism and disposition of the new retinoid 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl] benzoic acid. 1st communication: absorption, distribution, metabolism and excretion after topical application and subcutaneous administration in rats.
Mizojiri K; Okabe H; Sugeno K; Esumi Y; Takaichi M; Miyake T; Seki H; Inaba A
Arzneimittelforschung; 1997 Jan; 47(1):59-69. PubMed ID: 9037446
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of miglitol. Absorption, distribution, metabolism, and excretion following administration to rats, dogs, and man.
Ahr HJ; Boberg M; Brendel E; Krause HP; Steinke W
Arzneimittelforschung; 1997 Jun; 47(6):734-45. PubMed ID: 9239452
[TBL] [Abstract][Full Text] [Related]
12. Safety and pharmacokinetics of Bevirimat (PA-457), a novel inhibitor of human immunodeficiency virus maturation, in healthy volunteers.
Martin DE; Blum R; Wilton J; Doto J; Galbraith H; Burgess GL; Smith PC; Ballow C
Antimicrob Agents Chemother; 2007 Sep; 51(9):3063-6. PubMed ID: 17576843
[TBL] [Abstract][Full Text] [Related]
13. Metabolism and disposition of the HIV-1 protease inhibitor ritonavir (ABT-538) in rats, dogs, and humans.
Denissen JF; Grabowski BA; Johnson MK; Buko AM; Kempf DJ; Thomas SB; Surber BW
Drug Metab Dispos; 1997 Apr; 25(4):489-501. PubMed ID: 9107549
[TBL] [Abstract][Full Text] [Related]
14. Multiple-dose pharmacokinetics and safety of bevirimat, a novel inhibitor of HIV maturation, in healthy volunteers.
Martin DE; Blum R; Doto J; Galbraith H; Ballow C
Clin Pharmacokinet; 2007; 46(7):589-98. PubMed ID: 17596104
[TBL] [Abstract][Full Text] [Related]
15. Disposition of salmeterol xinafoate in laboratory animals and humans.
Manchee GR; Barrow A; Kulkarni S; Palmer E; Oxford J; Colthup PV; Maconochie JG; Tarbit MH
Drug Metab Dispos; 1993; 21(6):1022-8. PubMed ID: 7905380
[TBL] [Abstract][Full Text] [Related]
16. Absorption, distribution, metabolism, and excretion of atevirdine in the rat.
Chang M; Sood VK; Wilson GJ; Kloosterman DA; Sanders PE; Schuette MR; Judy RW; Voorman RL; Maio SM; Slatter JG
Drug Metab Dispos; 1998 Oct; 26(10):1008-18. PubMed ID: 9763407
[TBL] [Abstract][Full Text] [Related]
17. Metabolism, disposition, excretion, and pharmacokinetics of levormeloxifene, a selective estrogen receptor modulator, in the rat.
Mountfield RJ; Kiehr B; John BA
Drug Metab Dispos; 2000 May; 28(5):503-13. PubMed ID: 10772628
[TBL] [Abstract][Full Text] [Related]
18. Disposition of [14C]avitriptan in rats and humans.
Marathe PH; Greene DS; Barbhaiya RH
Drug Metab Dispos; 1997 Jul; 25(7):881-8. PubMed ID: 9224783
[TBL] [Abstract][Full Text] [Related]
19. The metabolic disposition of aprepitant, a substance P receptor antagonist, in rats and dogs.
Huskey SE; Dean BJ; Doss GA; Wang Z; Hop CE; Anari R; Finke PE; Robichaud AJ; Zhang M; Wang B; Strauss JR; Cunningham PK; Feeney WP; Franklin RB; Baillie TA; Chiu SH
Drug Metab Dispos; 2004 Feb; 32(2):246-58. PubMed ID: 14744948
[TBL] [Abstract][Full Text] [Related]
20. Estimating mass balance for inhaled drugs in humans: an example with a VLA-4 antagonist, IVL745.
Rohatagi S; Shah B; Zhang J; Zeng Z; Kirkesseli S; Jensen BK
J Clin Pharmacol; 2004 Apr; 44(4):348-58. PubMed ID: 15051741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
